Kigtropin é o nome de marca para humanos criados sinteticamente,Kigtropin é a melhor somatropina HGH no mercado os resultados mais eficazes e melhores que uma pessoa pode obter, kigtropin é projetado. Nós enviamos o pedido dos EUA, porcelana, e UE. Somos um distribuidor de?kigtropin HGH atacadista de? kigtropin HGH, Por favor, obtenha mais kigtropin HGH China (Continente) fabricantes, exportadores, fornecedores, fábricas, Empresas da China .
Kigtropin é um hormônio de crescimento humano (hGH) Somatropina produzida com tecnologia de DNA recombinante idêntica ao HGH produzido naturalmente pelo corpo.
Falha de crescimento de crianças devido à deficiência endógena de hormônio do crescimento (GHD).
Em adultos com deficiência de hormônio do crescimento,KIGTROPIN reduz a massa gorda,aumenta a massa muscular e melhora a energia,vitalidade e bem-estar subjetivo. Em pacientes que sofrem de queimaduras graves,Perda muscular associada à AIDS,ou passando por grandes operações,KIGTROPIN promove a cicatrização de feridas,atenua a resposta catabólica de proteínas e melhora a condição de nitrogênio de todo o corpo após a operação.
Kigtropin comes as a freeze dried white powder – 10 x 10 IU (3.3 mg) vials per box. Like several others it started as a made up brand name which became popular due to good reviews in the bodybuilding community. It is manufactured by an unknown Chinese lab – which seems to be a common practice some Chinese companies use to avoid the HGH legality issues
In patients who continue growth hormone therapy after childhood GHD, the recommended dose to restart is 0.2 - 0.5 mg per day. The dose should be gradually increased or decreased according to individual patient requirements as determined by the IGF-I concentration.
In adults with adult-onset GHD, therapy should start with a low dose, 0.15 - 0.3 mg per day. The dose should be gradually increased according to individual patient requirements as determined by the IGF-I concentration.
In both cases treatment goal should be insulin-like growth factor (IGF-I) concentrations within 2 SDS from the age corrected mean. Patients with normal IGF-I concentrations at the start of the treatment should be administered growth hormone up to an IGF-I level into the upper range of normal, not exceeding the 2 SDS. Clinical response and side effects may also be used as guidance for dose titration. It is recognized that there are patients with GHD who do not normalize IGF-I levels despite a good clinical response, and thus do not require dose escalation. The maintenance dose rarely exceeds 1.0 mg per day. Women may require higher doses than men, with men showing an increasing IGF-I sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen replacement are under-treated while men are over-treated. The accuracy of the growth hormone dose should therefore be controlled every 6 months. As normal physiological growth hormone production decreases with age, dose requirements may be reduced.
Kigtropin for Elderly:
In patients above 60 years, therapy should start with a dose of 0.1 - 0.2 mg per day and should be slowly increased according to individual patient requirements. The minimum effective dose should be used. The maintenance dose in these patients seldom exceeds 0.5 mg per day.
How to Inject:
The subcutaneous administration of growth hormone may lead to loss or increase of adipose tissue at the injection site. Portanto, injection sites should be alternated.
The injection should be given subcutaneously and the site varied to prevent lipoatrophy.
